ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 677,66
1,18%
DAX
18 001,60
0,54%
Brent Oil
83,115
-0,62%
Bitcoin
62 010,89
4,90%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Enanta Pharmaceuticals Inc (ENTA)

  7. Enanta Pharmaceuticals Inc (ENTA) Actualités

ENTA

Enanta Pharmaceuticals (ENTA)

Enanta Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ENTA
DateHeureSourceTitreSymboleSociété
30/04/202413h10Business WireEnanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ENTAEnanta Pharmaceuticals Inc
30/04/202413h00Business WireEnanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal OfficerNASDAQ:ENTAEnanta Pharmaceuticals Inc
29/04/202413h00Business WireEnanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024NASDAQ:ENTAEnanta Pharmaceuticals Inc
17/04/202413h00Business WireEnanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024NASDAQ:ENTAEnanta Pharmaceuticals Inc
08/03/202423h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTAEnanta Pharmaceuticals Inc
06/03/202413h00Business WireEnanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma ConferenceNASDAQ:ENTAEnanta Pharmaceuticals Inc
27/02/202419h11Edgar (US Regulatory)Form SCHEDULE 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ENTAEnanta Pharmaceuticals Inc
14/02/202420h26Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ENTAEnanta Pharmaceuticals Inc
09/02/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ENTAEnanta Pharmaceuticals Inc
08/02/202422h24Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ENTAEnanta Pharmaceuticals Inc
07/02/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ENTAEnanta Pharmaceuticals Inc
07/02/202422h01Business WireEnanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2023 with Webcast and Conference Call Today at 4:30 p.m. ETNASDAQ:ENTAEnanta Pharmaceuticals Inc
06/02/202413h00Business WireEnanta Pharmaceuticals to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:ENTAEnanta Pharmaceuticals Inc
31/01/202413h00Business WireEnanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2023NASDAQ:ENTAEnanta Pharmaceuticals Inc
26/01/202422h39Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:ENTAEnanta Pharmaceuticals Inc
26/01/202422h37Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ENTAEnanta Pharmaceuticals Inc
26/01/202422h25Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ENTAEnanta Pharmaceuticals Inc
11/01/202422h15Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ENTAEnanta Pharmaceuticals Inc
04/01/202413h00Business WireEnanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2024 Outlook at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ENTAEnanta Pharmaceuticals Inc
03/01/202413h00Business WireEnanta Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ENTAEnanta Pharmaceuticals Inc
12/12/202323h16Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ENTAEnanta Pharmaceuticals Inc
22/11/202322h38Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ENTAEnanta Pharmaceuticals Inc
22/11/202322h21Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ENTAEnanta Pharmaceuticals Inc
22/11/202322h12Edgar (US Regulatory)Form POSASR - Post-effective Amendment to an automatic shelf registration statementNASDAQ:ENTAEnanta Pharmaceuticals Inc
22/11/202313h00Business WireEnanta Pharmaceuticals to Participate at Evercore ISI HealthCONx ConferenceNASDAQ:ENTAEnanta Pharmaceuticals Inc
20/11/202322h01Business WireEnanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2023, with Webcast and Conference Call Today at 4:30 p.m. ETNASDAQ:ENTAEnanta Pharmaceuticals Inc
20/11/202312h25IH Market NewsMonday’s Wall Street Highlights: GM, Microsoft, Citigroup, Amazon, and moreNASDAQ:ENTAEnanta Pharmaceuticals Inc
13/11/202313h00Business WireEnanta Pharmaceuticals to Host Conference Call on November 20 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Full Year Ended September 30, 2023NASDAQ:ENTAEnanta Pharmaceuticals Inc
13/10/202313h00Business WireEnanta Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss Advances in the Treatment Landscape for Respiratory Syncytial Virus (RSV) and its Proprietary RSV PipelineNASDAQ:ENTAEnanta Pharmaceuticals Inc
17/09/202318h00Business WireEnanta Pharmaceuticals to Present Data for EDP-323, its Oral, Once-Daily, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at the 9th ESWI Influenza ConferenceNASDAQ:ENTAEnanta Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ENTA

Dernières Valeurs Consultées

EU
CAP
Capgemini
COIN
ETHUSD
Ethereum
EU
RI
Pernod Ricard
NYSE
NKE
Nike
EU
BEL20
Bel 20
EU
BN
Danone
EU
AF
Air FranceKLM
EU
LR
Legrand
NYSE
KO
Coca Cola
NYSE
JPM
JP Morgan Chase
EU
RNO
Renault
NASDAQ
GOOGL
Alphabet
EU
MC
Lvmh Moet Hennessy Louis...
EU
DG
Vinci
EU
HO
Thales
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés